Arxx Therapeutics

Developer of monoclonal antibody for fibrotic disease

placeOslo, Oslo, Norway calendar_todayFounded 2019 groups2 employees language arxxtx.com

Registered entities

Innovation

2 patent families (1 granted) — focus: Chemistry & metallurgy; filing pace slowing. Cited 111 times.

YearFilings
20222
20232
20241
20251

Investor mix

7 investors on record; lead investors include Rasmussengruppen, Investinor, Altitude, Sarsia Seed.

Investor typeCountShare
Venture capital343%
Other / undisclosed457%
Coming soon